MN-KINDEVA-DRUG-DELIVERY
Kindeva Drug Delivery (Kindeva), a global leader in drug-device combination products, today announced its investment in a second manufacturing line for the production of pressurized metered-dose inhaler (pMDI) products containing low-GWP (Global Warming Potential) propellants in its Loughborough, U.K., facility.
This new line will be capable of handling both HFA-152a and HFO-1234ze propellants — that have a GWP of 90% and 99.9% lower than the industry standard HFA-134a, respectively — and is anticipated to be operational in 2026. Kindeva’s first pMDI manufacturing line, which was announced in 2022, is in its installation phase and will be completed later in 2024.
Milton Boyer, Kindeva’s CEO said: “This investment will bring to the market one of the first large-volume commercial green propellant lines to the contract manufacturing market capable of supplying up to 50 million pMDI units per year. This second investment in low-GWP GMP manufacturing capacity further underscores Kindeva’s commitment to enable the pharmaceutical industry to meet its sustainability goals, whilst ensuring patient choice is not compromised. With our first GMP low-GWP manufacturing line expected to be operational in 2024, we are proud to be leading the transition to low-GWP propellants by ensuring the capacity is available.”
The new manufacturing line meets an increased customer demand for more sustainable pMDI products and considers the recent adoption of F-gas legislation in the European Union. Phase down of the existing propellants will commence in 2027 in the EU and be completed by the end of 2029.
Boyer continued: “With a track record of nearly 70 years in pMDIs — including the invention of the pMDI in 1956 and leading the CFC- to HFA-inhaler transition in the 1990s — we are excited to be a part of this industry-wide switch in the pMDI space. Kindeva is doing everything we can to ensure a greener future for all stakeholders by doubling down on our commitment to the low-GWP evolution.”
This announcement marks a continuation in the next chapter of Kindeva’s leadership in driving sustainable innovation in pMDIs and, more broadly, complex drug and combination products.
About Kindeva Drug Delivery
Kindeva Drug Delivery is a global contract development and manufacturing organization focused on drug-device combination products. We develop and manufacture products across a broad range of drug-delivery formats, including pulmonary & nasal, injectable, and transdermal. Our service offerings span early-stage feasibility through commercial scale drug product fill-finish, container closure system manufacturing, and drug-device product assembly. Kindeva serves a global client base from our state-of-the-art manufacturing, research, and development facilities located across the U.S. and U.K.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240502795839/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
PHC and CCRM Collaborate to Develop Primary T-Cell Expansion Culture Processesto Enhance Efficiency and Improve Cell Quality10.2.2025 06:00:00 CET | Press release
PHC Corporation has signed a Master Collaboration Agreement with CCRM to work together on the development of primary T-cell(*1) expansion culture processes that will seek to accelerate the manufacturing of cell and gene therapy (CGT) products. This joint initiative will integrate “LiCellGrowTM(*2), PHC’s cell expansion system under development, with CCRM’s deep knowledge of regenerative medicine and biomanufacturing to establish new culture processes to improve cell culture efficiency and quality for CGTs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250209611769/en/ *For research purposes only. Anticipated visual image of LiCellGrow. All features subject to change. (Graphic: Business Wire) Primary T-cells are used in process development and manufacturing for CGTs, such as in CAR-T cell therapy.(*3) However, primary T-cells derived directly from patients often exhibit significant variability in growth rates and quality, ma
NTT DATA Unveils Global Insights on GenAI Adoption in Banking: Divergent Strategies for Boosting Productivity vs. Cutting Costs10.2.2025 05:00:00 CET | Press release
Research from NTT DATA finds that as GenAI adoption rises, new pressures on return of investment are at the forefront of the challenges facing the banking industry. NTT DATA, a global digital business and IT services leader, has today launched a new global research report uncovering the use of generative AI (GenAI) in the banking sector worldwide. The report, titled “Intelligent banking in the Age of AI,” has found that despite the growing adoption of GenAI technology in the banking industry, banks and financial institutions are split when it comes to outcome-based strategies – only half of banks (50%) see it as a tool for improving productivity and efficiency. Similarly, half (49%) believe it can be used for reducing operational IT spend. Transforming Banking Through GenAI GenAI is more disruptive than any previous advance in banking technology. It is less a question of if, but when banks embrace this technology, due to its transformative ability to embed intelligence at every layer o
Revolutionizing Air Compressor Operation: ELGi Unveils Ground-breaking “STABILISOR” Technology10.2.2025 04:30:00 CET | Press release
Setting New Standards in Compressed Air Reliability, Energy Costs, and Variable Flow In a significant leap forward for industrial air compression, Elgi Equipments (BSE: 522074; NSE: ELGIEQUIP), one of the world's leading air-compressor manufacturers with over 64 years of compressed air excellence, today announced the introduction of its pioneering compressed air stabilization technology. Designed to revolutionize the way compressors operate in plants with dynamic air demand, the STABILISOR system aims to address the longstanding challenges of unstable compressor performance, inefficiency, and excessive wear caused by frequent load/unload cycles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250204651563/en/ Patented Compressed Air Stabilization Technology (Graphic: Elgi Equipments) In industrial settings, the gap between compressor capacity and plant air demand is inherently dynamic. This variability leads to frequent cut-i
Andersen Global tilføjer større bredde til sit fodaftryk i Europa med Allyum i Belgien8.2.2025 14:17:00 CET | Pressemeddelelse
Andersen Global styrker sin platform i Europa gennem en samarbejdsaftale med Allyum, et førende Mergers & Acquisitions (M&A) firma i Belgien, hvilket betyder en endnu bredere skattemæssig og juridisk platform i regionen. Fra stiftelsen i 2004 har administrerende direktør Raphaël Abou, Allyum, specialiseret sig i omfattende finansielle tjenester til mid-cap virksomheder med et specifikt fokus på styring fra start til slut af transaktioner på salgssiden. Firmaet er eksperter inden for fusioner og opkøb, private investeringer, børsnoteringer, corporate venturing, aktionæromstrukturering samt finansiel analyse og planlægning. "I løbet af det seneste årti har vi hjulpet hundredvis af virksomheder med at foretage deres transaktioner og udviklet fremragende relationer med investeringsfondene i vores region," siger Raphaël. "Vores samarbejde med Andersen Global bliver en spændende mulighed for at anvende vores omfattende tilgang til finansiel rådgivning gennem den bedste globale platform." "Vi
Duravant to Acquire Pattyn, Provider of Packaging Automation Systems for Bulk and Industrial Applications7.2.2025 15:00:00 CET | Press release
Automation solutions leader Duravant has signed a definitive agreement to acquire Pattyn. Duravant LLC (“Duravant”), a global engineered equipment and automation solutions provider to the food processing, packaging and material handling sectors, announced today that it has entered into a definitive agreement to acquire the Pattyn Group BV (‘Pattyn”), a designer and manufacturer of automation systems specializing in B2B packaging. Pattyn is recognized as the premier leader for delivering comprehensive automation solutions and value-added services for bag-in-box packaging applications. Headquartered in Bruges, Belgium, Pattyn has over 70 years of expertise in machinery design and turnkey systems for counting, weighing, filling, and packing technologies for food, ingredients, and various non-food sectors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250207117623/en/ “We are extremely excited to partner with Pattyn,” said Mike
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom